Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo

Pavel Bouchal, Jiri Jarkovsky, Kristyna Hrazdilova, Monika Dvorakova, Iva Struharova, Lenka Hernychova, Jiri Damborsky, Petr Sova, Borivoj Vojtesek

. 2011 ; 9 (1) : 68.

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc13015788

Grant support
NS9812 MZ0 CEP Register

BACKGROUND: The initial pharmacokinetic study of a new anticancer agent (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum (IV) (LA-12) was complemented by proteomic screening of rat plasma. The objective of the study was to identify new LA-12 target proteins that serve as markers of LA-12 treatment, response and therapy monitoring. METHODS: Proteomic profiles were measured by surface-enhanced laser desorption-ionization time-of-flight mass spectrometry (SELDI-TOF MS) in 72 samples of rat plasma randomized according to LA-12 dose and time from administration. Correlation of 92 peak clusters with platinum concentration was evaluated using Spearman correlation analysis. RESULTS: We identified Retinol-binding protein 4 (RBP4) whose level correlated with LA-12 level in treated rats. Similar results were observed in randomly selected patients involved in Phase I clinical trials. CONCLUSIONS: RBP4 induction is in agreement with known RBP4 regulation by amantadine and cisplatin. Since retinol metabolism is disrupted in many cancers and inversely associates with malignancy, these data identify a potential novel mechanism for the action of LA-12 and other similar anti-cancer drugs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13015788
003      
CZ-PrNML
005      
20190204093612.0
007      
ta
008      
130424s2011 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/1477-5956-9-68 $2 doi
035    __
$a (PubMed)22040120
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Bouchal, Pavel, $u Masaryk University, Faculty of Science, Department of Biochemistry, Brno, Czech Republic; Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic. vojtesek@mou.cz. $d 1975- $7 xx0128495
245    14
$a The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo / $c Pavel Bouchal, Jiri Jarkovsky, Kristyna Hrazdilova, Monika Dvorakova, Iva Struharova, Lenka Hernychova, Jiri Damborsky, Petr Sova, Borivoj Vojtesek
520    9_
$a BACKGROUND: The initial pharmacokinetic study of a new anticancer agent (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum (IV) (LA-12) was complemented by proteomic screening of rat plasma. The objective of the study was to identify new LA-12 target proteins that serve as markers of LA-12 treatment, response and therapy monitoring. METHODS: Proteomic profiles were measured by surface-enhanced laser desorption-ionization time-of-flight mass spectrometry (SELDI-TOF MS) in 72 samples of rat plasma randomized according to LA-12 dose and time from administration. Correlation of 92 peak clusters with platinum concentration was evaluated using Spearman correlation analysis. RESULTS: We identified Retinol-binding protein 4 (RBP4) whose level correlated with LA-12 level in treated rats. Similar results were observed in randomly selected patients involved in Phase I clinical trials. CONCLUSIONS: RBP4 induction is in agreement with known RBP4 regulation by amantadine and cisplatin. Since retinol metabolism is disrupted in many cancers and inversely associates with malignancy, these data identify a potential novel mechanism for the action of LA-12 and other similar anti-cancer drugs.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jarkovsky, Jiri $u Masaryk University, Institute of Biostatistics and Analyses, Brno, Czech Republic
700    1_
$a Hrazdilova, Kristyna $u Masaryk Memorial Cancer Institute, Department of Oncological and Experimental Pathology, Brno, Czech Republic
700    1_
$a Dvorakova, Monika $u Masaryk University, Faculty of Science, Department of Biochemistry, Brno, Czech Republic; Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic
700    1_
$a Struharova, Iva $u Masaryk University, Faculty of Science, Department of Biochemistry, Brno, Czech Republic; Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic
700    1_
$a Hernychova, Lenka $u Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic; University of Defence, Faculty of Military Health Sciences, Institute of Molecular Pathology, Hradec Kralove, Czech Republic
700    1_
$a Damborsky, Jiri $u Masaryk University, Faculty of Science, Department of Experimental Biology, Brno, Czech Republic; Centre of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic
700    1_
$a Sova, Petr $u Platinum Pharmaceuticals a.s., Brno, Czech Republic
700    1_
$a Vojtesek, Borivoj $u Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic
773    0_
$w MED00008250 $t Proteome science $x 1477-5956 $g Roč. 9, č. 1 (2011), s. 68
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22040120 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130424 $b ABA008
991    __
$a 20190204093849 $b ABA008
999    __
$a ind $b bmc $g 978989 $s 814109
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 9 $c 1 $d 68 $i 1477-5956 $m Proteome science $n Proteome Sci $x MED00008250
GRA    __
$a NS9812 $p MZ0
LZP    __
$a Pubmed-20130424

Find record

Citation metrics

Archiving options